-
1
-
-
0036570099
-
Timing of new black box warnings and withdrawals for prescription medications
-
Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-2220 (Pubitemid 34441937)
-
(2002)
Journal of the American Medical Association
, vol.287
, Issue.17
, pp. 2215-2220
-
-
Lasser, K.E.1
Allen, P.D.2
Woolhandler, S.J.3
Himmelstein, D.U.4
Wolfe, S.M.5
Bor, D.H.6
-
3
-
-
12444320258
-
Coxibs, science, and the public trust
-
Solomon DH, Avorn J. Coxibs, science, and the public trust. Arch Intern Med 2005;165:158-160
-
(2005)
Arch Intern Med
, vol.165
, pp. 158-160
-
-
Solomon, D.H.1
Avorn, J.2
-
4
-
-
0037190089
-
Postmarketing surveillance and black box warnings
-
Graham GK. Postmarketing surveillance and black box warnings. JAMA 2002;288:955-959
-
(2002)
JAMA
, vol.288
, pp. 955-959
-
-
Graham, G.K.1
-
5
-
-
0033559723
-
Postmarketing surveillance: Strengths and limitations. the flucloxacillin-dicloxacillin story
-
McNeil JJ, Grabsch EA, McDonald MM. Postmarketing surveillance: strengths and limitations-the flucloxacillindicloxacillin story. Med J Aust 1999;170:270-273 (Pubitemid 29129345)
-
(1999)
Medical Journal of Australia
, vol.170
, Issue.6
, pp. 270-273
-
-
McNeil, J.J.1
Grabsch, E.A.2
McDonald, M.M.3
-
6
-
-
0035038538
-
The use of evidence in pharmacovigilance: Case reports as the reference source for drug withdrawals
-
DOI 10.1007/s002280100265
-
Arnaiz JA, Carne X, Riba N, Codina C, Ribas J, Trilla A. The use of evidence in pharmacovigilance: case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol 2001;57:89-91 (Pubitemid 32391420)
-
(2001)
European Journal of Clinical Pharmacology
, vol.57
, Issue.1
, pp. 89-91
-
-
Arnaiz, J.A.1
Carne, X.2
Riba, N.3
Codina, C.4
Ribas, J.5
Trilla, A.6
-
8
-
-
0037236850
-
Consumer adverse drug reaction reporting: A new step in pharmacovigilance?
-
van Grootheest K, de Graaf L, de Jong-van den Berg LT. Consumer adverse drug reaction reporting: a new step in pharmacovigilance? Drug Saf 2003;26:211-217
-
(2003)
Drug Saf
, vol.26
, pp. 211-217
-
-
Van Grootheest, K.1
De Graaf, L.2
De Jong-van Den Berg, L.T.3
-
9
-
-
34548058076
-
Physician response to patient reports of adverse drug effects: Implications for patient-targeted adverse effect surveillance
-
DOI 10.2165/00002018-200730080-00003
-
Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf 2007;30:669-675 (Pubitemid 47295826)
-
(2007)
Drug Safety
, vol.30
, Issue.8
, pp. 669-675
-
-
Golomb, B.A.1
McGraw, J.J.2
Evans, M.A.3
Dimsdale, J.E.4
-
10
-
-
0345689707
-
A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behaviour with paroxetine
-
Medawar C, Herxheimer A. A comparison of adverse drug reaction reports from professionals and users, relating to risk of dependence and suicidal behavior. Int J Risk Safety Med 2003-2004;16:5-19 (Pubitemid 37475764)
-
(2003)
International Journal of Risk and Safety in Medicine
, vol.16
, Issue.1
, pp. 5-19
-
-
Medawar, C.1
Herxheimer, A.2
-
11
-
-
0035372490
-
Summary of the third report of the national cholesterol education program adult treatment panel III
-
Lepor NE, Vogel RE. Summary of the third report of the national cholesterol education program adult treatment panel III. Rev Cardiovasc Med 2001;2:160-165
-
(2001)
Rev Cardiovasc Med
, vol.2
, pp. 160-165
-
-
Lepor, N.E.1
Vogel, R.E.2
-
12
-
-
8844246477
-
Implications of recent clinical trials for the national cholesterol education program ault treatment panel III guidelines
-
Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program ault treatment panel III guidelines. Arterioscler Thromb Vasc Biol 2004;24:e149-61
-
(2004)
Arterioscler Thromb Vasc Biol
, vol.24
-
-
Grundy, S.M.1
Cleeman, J.I.2
Merz, C.N.3
-
14
-
-
0032769877
-
Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias
-
Wierzbicki AS, Lumb PJ, Semra Y, Chik G, Christ ER, Crook MA. Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM 1999;92:387-394 (Pubitemid 29346883)
-
(1999)
QJM - Monthly Journal of the Association of Physicians
, vol.92
, Issue.7
, pp. 387-394
-
-
Wierzbicki, A.S.1
Lumb, P.J.2
Semra, Y.3
Chik, G.4
Christ, E.R.5
Crook, M.A.6
-
15
-
-
0036787034
-
Statin-associated myopathy with normal creatine kinase levels
-
Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-585
-
(2002)
Ann Intern Med
, vol.137
, pp. 581-585
-
-
Phillips, P.S.1
Haas, R.H.2
Bannykh, S.3
-
17
-
-
20444469339
-
How common is rhabdomyolysis in patients receiving lipid-lowering therapy?
-
Phillips PS. How common is rhabdomyolysis in patients receiving lipid-lowering therapy? Nat Clin Pract Cardiovasc Med 2005;2:130-131
-
(2005)
Nat Clin Pract Cardiovasc Med
, vol.2
, pp. 130-131
-
-
Phillips, P.S.1
-
19
-
-
33847243361
-
Systematic review and meta-analysis of clinically relevant adverse events from HMG-CoA reductase inhibitor trials worldwide from 1982 to present
-
McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG-CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007;16:132-143
-
(2007)
Pharmacoepidemiol Drug Saf
, vol.16
, pp. 132-143
-
-
McClure, D.L.1
Valuck, R.J.2
Glanz, M.3
Hokanson, J.E.4
-
21
-
-
33746742345
-
Short-term memory loss associated with rosuvastatin
-
DOI 10.1592/phco.26.8.1190
-
Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-term memory loss associated with rosuvastatin. Pharmacotherapy 2006;26:1190-1192 (Pubitemid 44167829)
-
(2006)
Pharmacotherapy
, vol.26
, Issue.8 I
, pp. 1190-1192
-
-
Galatti, L.1
Polimeni, G.2
Salvo, F.3
Romani, M.4
Sessa, A.5
Spina, E.6
-
22
-
-
33947247905
-
Psychiatric adverse reactions with statins, fibrates and ezetimibe: Implications for the use of lipid-lowering agents
-
Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipidlowering agents. Drug Saf 2007;30:195-201 (Pubitemid 46425633)
-
(2007)
Drug Safety
, vol.30
, Issue.3
, pp. 195-201
-
-
Tatley, M.1
Savage, R.2
-
23
-
-
0004836497
-
Cognitive impairment associated with atorvastatin
-
abstract
-
King DS, Jones DW, Wofford MR, Harkins K, Harrell K, Kelley KW. Cognitive impairment associated with atorvastatin [abstract]. Pharmacotherapy 2001;21:371
-
(2001)
Pharmacotherapy
, vol.21
, pp. 371
-
-
King, D.S.1
Jones, D.W.2
Wofford, M.R.3
Harkins, K.4
Harrell, K.5
Kelley, K.W.6
-
24
-
-
0344011137
-
Cognitive Impairment Associated with Atorvastatin and Simvastatin
-
DOI 10.1592/phco.23.15.1663.31953
-
King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003;23:1663-1667 (Pubitemid 37485319)
-
(2003)
Pharmacotherapy
, vol.23
, Issue.12 I
, pp. 1663-1667
-
-
King, D.S.1
Wilburn, A.J.2
Wofford, M.R.3
Harrell, T.K.4
Lindley, B.J.5
Jones, D.W.6
-
26
-
-
0038381775
-
Statin-associated memory loss: Analysis of 60 case reports and review of the literature
-
DOI 10.1592/phco.23.7.871.32720
-
Wagstaff LR, Mitton MW, McLendon Arvik B, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003;23:871-880 (Pubitemid 36875671)
-
(2003)
Pharmacotherapy
, vol.23
, Issue.7
, pp. 871-880
-
-
Wagstaff, L.R.1
Mitton, M.W.2
Arvik, B.M.3
Doraiswamy, P.M.4
-
27
-
-
0034015649
-
Effects of lovastatin on cognitive function and psychological well-being
-
DOI 10.1016/S0002-9343(00)00353-3, PII S0002934300003533
-
Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000;108:538-546 (Pubitemid 30249031)
-
(2000)
American Journal of Medicine
, vol.108
, Issue.7
, pp. 538-546
-
-
Muldoon, M.F.1
Barger, S.D.2
Ryan, C.M.3
Flory, J.D.4
Lehoczky, J.P.5
Matthews, K.A.6
Manuck, S.B.7
-
28
-
-
3843148550
-
Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults
-
DOI 10.1016/j.amjmed.2004.07.041, PII S0002934304005467
-
Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004;117:823-829 (Pubitemid 39602790)
-
(2004)
American Journal of Medicine
, vol.117
, Issue.11
, pp. 823-829
-
-
Muldoon, M.F.1
Ryan, C.M.2
Sereika, S.M.3
Flory, J.D.4
Manuck, S.B.5
-
29
-
-
4444364340
-
Low and lowered cholesterol and total mortality
-
DOI 10.1016/j.jacc.2004.06.022, PII S0735109704012148
-
Criqui MH, Golomb BA. Low and lowered cholesterol and total mortality. J Am Coll Cardiol 2004;44:1009-1010 (Pubitemid 39165134)
-
(2004)
Journal of the American College of Cardiology
, vol.44
, Issue.5
, pp. 1009-1010
-
-
Criqui, M.H.1
Golomb, B.A.2
-
30
-
-
0019799332
-
A method for estimating the probability of adverse drug reactions
-
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245
-
(1981)
Clin Pharmacol Ther
, vol.30
, pp. 239-245
-
-
Naranjo, C.A.1
Busto, U.2
Sellers, E.M.3
-
31
-
-
34248383514
-
Guidelines for submitting adverse event reports for publication
-
DOI 10.2165/00002018-200730050-00001
-
Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Drug Saf 2007;30:367-373 (Pubitemid 46740334)
-
(2007)
Drug Safety
, vol.30
, Issue.5
, pp. 367-373
-
-
Kelly, W.N.1
Arellano, F.M.2
Barnes, J.3
Bergman, U.4
Edwards, R.I.5
Fernandez, A.M.6
Freedman, S.B.7
Goldsmith, D.I.8
Huang, K.A.9
Jones, J.K.10
McLeay, R.11
Moore, N.12
Stather, R.H.13
Trenque, T.14
Troutman, W.G.15
Van Puijenbroek, E.16
Williams, F.17
Wise, R.P.18
-
32
-
-
0027987849
-
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
-
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-1389 (Pubitemid 24365311)
-
(1994)
Lancet
, vol.344
, Issue.8934
, pp. 1383-1389
-
-
Pedersen, T.R.1
-
33
-
-
0032487931
-
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
-
The Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group. [see comments]
-
The Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels [see comments]. N Engl J Med 1998;339:1349-1357
-
(1998)
N Engl J Med
, vol.339
, pp. 1349-1357
-
-
-
34
-
-
0037164314
-
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial
-
DOI 10.1016/S0140-6736(02)11600-X
-
Shepherd J, Blauw GJ, Murphy MB, et al, for the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630 (Pubitemid 35379733)
-
(2002)
Lancet
, vol.360
, Issue.9346
, pp. 1623-1630
-
-
Shepherd, J.1
Blauw, G.J.2
Murphy, M.B.3
Bollen, E.L.E.M.4
Buckley, B.M.5
Cobbe, S.M.6
Ford, I.7
Gaw, A.8
Hyland, M.9
Jukema, J.W.10
Kamper, A.M.11
Macfarlane, P.W.12
Meinders, A.E.13
Norrie, J.14
Packard, C.J.15
Perry, I.J.16
Stott, D.J.17
Sweeney, B.J.18
Twomey, C.19
Westendorp, R.G.J.20
more..
-
35
-
-
0035328131
-
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Additional perspectives on tolerability of long-term treatment with lovastatin
-
DOI 10.1016/S0002-9149(01)01464-3, PII S0002914901014643
-
Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/ TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001;87:1074-1079 (Pubitemid 32710322)
-
(2001)
American Journal of Cardiology
, vol.87
, Issue.9
, pp. 1074-1079
-
-
Downs, J.R.1
Clearfield, M.2
Tyroler, H.A.3
Whitney, E.J.4
Kruyer, W.5
Langendorfer, A.6
Zagrebelsky, V.7
Weis, S.8
Shapiro, D.R.9
Beere, P.A.10
Gotto, A.M.11
-
36
-
-
33847057676
-
Transient global amnesia in the district general hospital
-
DOI 10.1111/j.1742-1241.2006.00897.x
-
Larner AJ. Transient global amnesia in the district general hospital. Int J Clin Pract 2007;61:255-258 (Pubitemid 46271287)
-
(2007)
International Journal of Clinical Practice
, vol.61
, Issue.2
, pp. 255-258
-
-
Larner, A.J.1
-
37
-
-
43749105584
-
Transient global amnesia: A review
-
Shekhar R. Transient global amnesia: a review. Int J Clin Pract 2008;62:939-942
-
(2008)
Int J Clin Pract
, vol.62
, pp. 939-942
-
-
Shekhar, R.1
-
38
-
-
41049100570
-
-
update February Available from Accessed April 17, 2009
-
IMS Health. Commonly requested therapeutic class and product information (update February 2006). Available from http://www1.imshealth.com/ims/portal/ front/articleC/0,2777,65 99-18731-77056778,00.html. Accessed April 17, 2009
-
(2006)
Commonly Requested Therapeutic Class and Product Information
-
-
-
40
-
-
67650848354
-
-
Available from Accessed May 23, 2005
-
IMS Health. Lipitor leads the way in 2003. Available from http://www.ims-global.com/insight/news-story /0403/news- story-040316.htm. Accessed May 23, 2005
-
Lipitor Leads the Way in 2003
-
-
-
41
-
-
67650787324
-
-
Available from Accessed May 2, 2008
-
IMS Health. IMS global insights-IMS retail drug Monitor December 2007. Available from http://www.imshealth.com /web/content/0,3148,64576068-63872702- 70260998-8374658 5,00.html. Accessed May 2, 2008
-
IMS Global Insights-IMS Retail Drug Monitor December 2007
-
-
-
42
-
-
0030972796
-
The rule of 5 and the rule of 7 in lipid-lowering by statin drugs
-
Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106-107
-
(1997)
Am J Cardiol
, vol.80
, pp. 106-107
-
-
Roberts, W.C.1
-
43
-
-
42949138132
-
Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients
-
DOI 10.1592/phco.28.5.553
-
Miller AE, Hansen LB, Saseen JJ. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. Pharmacotherapy 2008;28:553-561 (Pubitemid 351620023)
-
(2008)
Pharmacotherapy
, vol.28
, Issue.5 PART 1
, pp. 553-561
-
-
Miller, A.E.1
Hansen, L.B.2
Saseen, J.J.3
-
44
-
-
0033745108
-
Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin
-
DOI 10.1067/mcp.2000.110537
-
Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68:391-400 (Pubitemid 30803528)
-
(2000)
Clinical Pharmacology and Therapeutics
, vol.68
, Issue.4
, pp. 391-400
-
-
Mazzu, A.L.1
Lasseter, K.C.2
Shamblen, E.C.3
Agarwal, V.4
Lettieri, J.5
Sundaresen, P.6
-
45
-
-
0032842577
-
Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: A multinational, randomised, double-blind study
-
Ose L, Luurila O, Eriksson J, Olsson A, Lithell H, Widgren B, for the Cerivastatin Study Group. Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, doubleblind study. Curr Med Res Opin 1999;15:228-240 (Pubitemid 29481481)
-
(1999)
Current Medical Research and Opinion
, vol.15
, Issue.3
, pp. 228-240
-
-
Ose, L.1
Luurila, O.2
Eriksson, J.3
Olsson, A.4
Lithell, H.5
Widgren, B.6
-
46
-
-
33746665298
-
Genetic risk factors associated with lipid-lowering drug-induced myopathies
-
DOI 10.1002/mus.20567
-
Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34:153-162 (Pubitemid 44167798)
-
(2006)
Muscle and Nerve
, vol.34
, Issue.2
, pp. 153-162
-
-
Vladutiu, G.D.1
Simmons, Z.2
Isackson, P.J.3
Tarnopolsky, M.4
Peltier, W.L.5
Barboi, A.C.6
Sripathi, N.7
Wortmann, R.L.8
Phillips, P.S.9
-
47
-
-
42449117901
-
Reduction in blood pressure with statins: Results from the UCSD statin study, a randomized trial
-
DOI 10.1001/archinte.168.7.721
-
Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Reductions in blood pressure with statins: results from the UCSD statin study, a randomized trial. Arch Intern Med 2008;168:721-727 (Pubitemid 351563955)
-
(2008)
Archives of Internal Medicine
, vol.168
, Issue.7
, pp. 721-727
-
-
Golomb, B.A.1
Dimsdale, J.E.2
White, H.L.3
Ritchie, J.B.4
Criqui, M.H.5
-
48
-
-
59549089180
-
Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism
-
Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373-418
-
(2008)
Am J Cardiovasc Drugs
, vol.8
, pp. 373-418
-
-
Golomb, B.A.1
Evans, M.A.2
-
49
-
-
49949104757
-
SLCO1B1 variants and statin-induced myopathy: A genomewide study
-
for The SEARCH Collaborative Group
-
Link E, Parish S, Armitage J, et al, for The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008;359:789-799
-
(2008)
N Engl J Med
, vol.359
, pp. 789-799
-
-
Link, E.1
Parish, S.2
Armitage, J.3
-
50
-
-
0032572086
-
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TEXCAPS, the Air Force/Texas coronary atherosclerosis prevention study
-
see comments
-
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TEXCAPS, the Air Force/Texas coronary atherosclerosis prevention study [see comments]. JAMA 1998;279:1615-1622
-
(1998)
JAMA
, vol.279
, pp. 1615-1622
-
-
Downs, J.R.1
Clearfield, M.2
Weis, S.3
-
51
-
-
0032487931
-
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
-
The Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group
-
The Long-Term Intervention with Pravastatin in Ischaemic Disease (Lipid) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357
-
(1998)
N Engl J Med
, vol.339
, pp. 1349-1357
-
-
-
52
-
-
33746895436
-
High-dose atorvastatin after stroke or transient ischemic attack
-
DOI 10.1056/NEJMoa061894
-
Amarenco P, Bogousslavsky J, Callahan A III, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559 (Pubitemid 44202151)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.6
, pp. 549-559
-
-
Amarenco, P.1
Bogousslavsky, J.2
Callahan III, A.3
Goldstein, L.B.4
Hennerici, M.5
Rudolph, A.E.6
Sillesen, H.7
Simunovic, L.8
Szarek, M.9
Welch, K.M.A.10
Zivin, J.A.11
-
53
-
-
0942265627
-
Conceptual Foundations of the UCSD Statin Study: A Randomized Controlled Trial Assessing the Impact of Statins on Cognition, Behavior, and Biochemistry
-
DOI 10.1001/archinte.164.2.153
-
Golomb BA, Criqui MH, White H, Dimsdale JE. Conceptual foundations of the UCSD statin study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry. Arch Intern Med 2004;164:153-162 (Pubitemid 38140401)
-
(2004)
Archives of Internal Medicine
, vol.164
, Issue.2
, pp. 153-162
-
-
Golomb, B.A.1
Criqui, M.H.2
White, H.3
Dimsdale, J.E.4
-
54
-
-
1542381000
-
The UCSD Statin Study: A randomized controlled trial assessing the impact of statins on selected noncardiac outcomes
-
DOI 10.1016/j.cct.2003.08.014, PII S0197245603001806
-
Golomb BA, Criqui MH, White HL, Dimsdale JE. The UCSD statin study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials 2004;25:178-202 (Pubitemid 38328758)
-
(2004)
Controlled Clinical Trials
, vol.25
, Issue.2
, pp. 178-202
-
-
Golomb, B.A.1
Criqui, M.H.2
White, H.L.3
Dimsdale, J.E.4
-
55
-
-
0032539874
-
10 deficiency
-
DOI 10.1016/S0022-510X(98)00006-9, PII S0022510X98000069
-
Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. J Neurol Sci 1998;156:41-46 (Pubitemid 28141037)
-
(1998)
Journal of the Neurological Sciences
, vol.156
, Issue.1
, pp. 41-46
-
-
Boitier, E.1
Degoul, F.2
Desguerre, I.3
Charpentier, C.4
Francois, D.5
Ponsot, G.6
Diry, M.7
Rustin, P.8
Marsac, C.9
-
56
-
-
0030975555
-
10 deficiency
-
Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology 1997;48:1238-1243 (Pubitemid 27240541)
-
(1997)
Neurology
, vol.48
, Issue.5
, pp. 1238-1243
-
-
Sobreira, C.1
Hirano, M.2
Shanske, S.3
Keller, R.K.4
Haller, R.G.5
Davidson, E.6
Santorelli, F.M.7
Miranda, A.F.8
Bonilla, E.9
Mojon, D.S.10
Barreira, A.A.11
King, M.P.12
Dimauro, S.13
-
57
-
-
0023267038
-
Clinical Improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy
-
Goda S, Hamada T, Ishimoto S, Kobayashi T, Goto I, Kuroiwa Y. Clinical Improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol 1987;234:62-63
-
(1987)
J Neurol
, vol.234
, pp. 62-63
-
-
Goda, S.1
Hamada, T.2
Ishimoto, S.3
Kobayashi, T.4
Goto, I.5
Kuroiwa, Y.6
-
59
-
-
33745739157
-
Circulating cholesterol levels, apolipoprotein e genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: Results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial
-
DOI 10.1111/j.1600-0404.2006.00690.x
-
Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's disease cholesterol-lowering treatment (ADCLT) trial. Acta Neurol Scand Suppl 2006;185:3-7 (Pubitemid 44015218)
-
(2006)
Acta Neurologica Scandinavica
, vol.114
, Issue.SUPPL. 185
, pp. 3-7
-
-
Sparks, D.L.1
Connor, D.J.2
Sabbagh, M.N.3
Petersen, R.B.4
Lopez, J.5
Browne, P.6
-
60
-
-
0346872978
-
Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials
-
Vrecer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke: meta-analysis of randomized trials. Int J Clin Pharmacol Ther 2003;41:567-577 (Pubitemid 37527563)
-
(2003)
International Journal of Clinical Pharmacology and Therapeutics
, vol.41
, Issue.12
, pp. 567-577
-
-
Vrecer, M.1
Turk, S.2
Drinovec, J.3
Mrhar, A.4
-
61
-
-
0037031061
-
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial
-
DOI 10.1016/S0140-6736(02)09327-3
-
Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002;360:7-22 (Pubitemid 34756487)
-
(2002)
Lancet
, vol.360
, Issue.9326
, pp. 7-22
-
-
Collins, R.1
Armitage, J.2
Parish, S.3
Sleight, P.4
Peto, R.5
-
62
-
-
0033153235
-
Compliance with Fluvastatin Treatment Characterization of the Noncompliant Population within a Population of 3845 Patients with Hyperlipidemia
-
DOI 10.1016/S0895-4356(99)00019-0, PII S0895435699000190
-
Bruckert E, Simonetta C, Giral P, for the CREOLE Study Team. Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. J Clin Epidemiol 1999;52: 589-594 (Pubitemid 29284819)
-
(1999)
Journal of Clinical Epidemiology
, vol.52
, Issue.6
, pp. 589-594
-
-
Bruckert, E.1
Simonetta, C.2
-
63
-
-
1642413628
-
Psychological and Cognitive Function: Predictors of Adherence with Cholesterol Lowering Treatment
-
Stilley CS, Sereika S, Muldoon MF, Ryan CM, Dunbar-Jacob J. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med 2004;27:117-124 (Pubitemid 38364891)
-
(2004)
Annals of Behavioral Medicine
, vol.27
, Issue.2
, pp. 117-124
-
-
Stilley, C.S.1
Sereika, S.2
Muldoon, M.F.3
Ryan, C.M.4
Dunbar-Jacob, J.5
-
64
-
-
67650806451
-
Do low dose statins affect cognition? Results of the UCSD statin study
-
abstract
-
Golomb BA, Dimsdale JE, White HL, Criqui MH. Do low dose statins affect cognition? Results of the UCSD statin study [abstract]. Circulation 2006;114(18 suppl):II-289
-
(2006)
Circulation
, vol.114
, Issue.18 SUPPL.
-
-
Golomb, B.A.1
Dimsdale, J.E.2
White, H.L.3
Criqui, M.H.4
-
66
-
-
0036714243
-
Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial
-
DOI 10.1002/ana.10292
-
Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, doubleblind trial. Ann Neurol 2002;52:346-350 (Pubitemid 35001502)
-
(2002)
Annals of Neurology
, vol.52
, Issue.3
, pp. 346-350
-
-
Simons, M.1
Schwarzler, F.2
Lutjohann, D.3
Von Bergmann, K.4
Beyreuther, K.5
Dichgans, J.6
Wormstall, H.7
Hartmann, T.8
Schulz, J.B.9
-
67
-
-
0036305918
-
The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment
-
Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 2002;57:M414-18 (Pubitemid 34733805)
-
(2002)
Journals of Gerontology - Series a Biological Sciences and Medical Sciences
, vol.57
, Issue.7
-
-
Hajjar, I.1
Schumpert, J.2
Hirth, V.3
Wieland, D.4
Eleazer, G.P.5
-
68
-
-
0034638746
-
Statins and the risk of dementia
-
Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-1631
-
(2000)
Lancet
, vol.356
, pp. 1627-1631
-
-
Jick, H.1
Zornberg, G.L.2
Jick, S.S.3
Seshadri, S.4
Drachman, D.A.5
-
69
-
-
0033772113
-
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme a reductase inhibitors
-
Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3- hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-1443 (Pubitemid 30769120)
-
(2000)
Archives of Neurology
, vol.57
, Issue.10
, pp. 1439-1443
-
-
Wolozin, B.1
Kellman, W.2
Ruosseau, P.3
Celesia, G.G.4
Siegel, G.5
-
70
-
-
34548291482
-
Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease
-
DOI 10.1212/01.wnl.0000277657.95487.1c, PII 0000611420070828000010
-
Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007;69:878-885 (Pubitemid 47329587)
-
(2007)
Neurology
, vol.69
, Issue.9
, pp. 878-885
-
-
Li, G.1
Larson, E.B.2
Sonnen, J.A.3
Shofer, J.B.4
Petrie, E.C.5
Schantz, A.6
Peskind, E.R.7
Raskind, M.A.8
Breitner, J.C.S.9
Montine, T.J.10
-
72
-
-
46049109962
-
Re: Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease
-
[correspondence]. author reply 2350
-
Golomb BA, Evans MA. Re: statin therapy is associated with reduced neuropathologic changes of Alzheimer disease [correspondence]. Neurology 2008;70:2349; author reply 2350
-
(2008)
Neurology
, vol.70
, pp. 2349
-
-
Golomb, B.A.1
Evans, M.A.2
-
73
-
-
0036350741
-
Estrogen and Alzheimer's disease: The story so far
-
Cholerton B, Gleason CE, Baker LD, Asthana S. Estrogen and Alzheimer's disease: the story so far. Drugs Aging 2002;19: 405-427 (Pubitemid 34941132)
-
(2002)
Drugs and Aging
, vol.19
, Issue.6
, pp. 405-427
-
-
Cholerton, B.1
Gleason, C.E.2
Baker, L.D.3
Asthana, S.4
-
74
-
-
0038724280
-
Effect of Estrogen Plus Progestin on Global Cognitive Function in Postmenopausal Women - The Women's Health Initiative Memory Study: A Randomized Controlled Trial
-
DOI 10.1001/jama.289.20.2663
-
Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the women's health initiative memory study-a randomized controlled trial. JAMA 2003;289:2663-2672 (Pubitemid 37430137)
-
(2003)
Journal of the American Medical Association
, vol.289
, Issue.20
, pp. 2663-2672
-
-
Rapp, S.R.1
Espeland, M.A.2
Shumaker, S.A.3
Henderson, V.W.4
Brunner, R.L.5
Manson, J.E.6
Gass, M.L.S.7
Stefanick, M.L.8
Lane, D.S.9
Hays, J.10
Johnson, K.C.11
Coker, L.H.12
Dailey, M.13
Bowen, D.14
-
75
-
-
0038386058
-
Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women - The Women's Health Initiative Memory Study: A Randomized Controlled Trial
-
DOI 10.1001/jama.289.20.2651
-
Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the women's health initiative memory study-a randomized controlled trial. JAMA 2003;289:2651-2662 (Pubitemid 37430136)
-
(2003)
Journal of the American Medical Association
, vol.289
, Issue.20
, pp. 2651-2662
-
-
Shumaker, S.A.1
Legault, C.2
Rapp, S.R.3
Thal, L.4
Wallace, R.B.5
Ockene, J.K.6
Hendrix, S.L.7
Jones III, B.N.8
Assaf, A.R.9
Jackson, R.D.10
Kotchen, J.M.11
Wassertheil-Smoller, S.12
Wactawski-Wende, J.13
-
76
-
-
36749076342
-
Statins and peripheral neuropathy
-
Adverse Drug Reactions Advisory Committee (ADRAC). Available from
-
Adverse Drug Reactions Advisory Committee (ADRAC). Statins and peripheral neuropathy. Aust Adverse Drug React Bull 2005;24(2):6. Available from http://www.tga. health.gov.au/ adr/aadrb/aadr0504.htm
-
(2005)
Aust Adverse Drug React Bull
, vol.24
, Issue.2
, pp. 6
-
-
-
77
-
-
4344658296
-
Statin-associated peripheral neuropathy: Review of the Literature
-
DOI 10.1592/phco.24.13.1194.38084
-
Chong PH, Boskovich A, Stevkovic N, Bartt RE. Statinassociated peripheral neuropathy: review of the literature. Pharmacotherapy 2004;24:1194-1203 (Pubitemid 39128843)
-
(2004)
Pharmacotherapy
, vol.24
, Issue.9
, pp. 1194-1203
-
-
Chong, P.H.1
Boskovich, A.2
Stevkovic, N.3
Bartt, R.E.4
-
78
-
-
0029062930
-
Peripheral neuropathy associated with simvastatin
-
Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 1995;58:625-628
-
(1995)
J Neurol Neurosurg Psychiatry
, vol.58
, pp. 625-628
-
-
Phan, T.1
McLeod, J.G.2
Pollard, J.D.3
Peiris, O.4
Rohan, A.5
Halpern, J.P.6
-
80
-
-
33750032561
-
Volume reduction of the entorhinal cortex in subjective memory impairment
-
Jessen F, Feyen L, Freymann K, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging 2006;27:1751-1756
-
(2006)
Neurobiol Aging
, vol.27
, pp. 1751-1756
-
-
Jessen, F.1
Feyen, L.2
Freymann, K.3
-
81
-
-
33748424515
-
Regionally specific atrophy of the corpus callosum in AD, MCI and cognitive complaints
-
DOI 10.1016/j.neurobiolaging.2005.09.035, PII S0197458005003027
-
Wang PJ, Saykin AJ, Flashman LA, et al. Regionally specific atrophy of the corpus callosum in AD, MCI and cognitive complaints. Neurobiol Aging 2006;27:1613-1617 (Pubitemid 44344845)
-
(2006)
Neurobiology of Aging
, vol.27
, Issue.11
, pp. 1613-1617
-
-
Wang, P.J.1
Saykin, A.J.2
Flashman, L.A.3
Wishart, H.A.4
Rabin, L.A.5
Santulli, R.B.6
McHugh, T.L.7
MacDonald, J.W.8
Mamourian, A.C.9
-
82
-
-
0032927814
-
Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition
-
Geerlings MI, Jonker C, Bouter LM, Ader HJ, Schmand B. Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. Am J Psychiatry 1999;156:531-537 (Pubitemid 29162972)
-
(1999)
American Journal of Psychiatry
, vol.156
, Issue.4
, pp. 531-537
-
-
Geerlings, M.I.1
Jonker, C.2
Bouter, L.M.3
Ader, H.J.4
Schmand, B.5
-
83
-
-
17444396712
-
Cognitive deficits 3 to 6 years before dementia onset in a population sample: The Honolulu-Asia Aging Study
-
DOI 10.1111/j.1532-5415.2005.53163.x
-
Jorm AF, Masaki KH, Petrovitch H, Ross GW, White LR. Cognitive deficits 3 to 6 years before dementia onset in a population sample: the Honolulu-Asia aging study. J Am Geriatr Soc 2005;53:452-455 (Pubitemid 41623524)
-
(2005)
Journal of the American Geriatrics Society
, vol.53
, Issue.3
, pp. 452-455
-
-
Jorm, A.F.1
Masaki, K.H.2
Petrovitch, H.3
Ross, G.W.4
White, L.R.5
-
84
-
-
16644392557
-
Subjective memory deterioration and future dementia in people aged 65 and older
-
DOI 10.1111/j.1532-5415.2004.52568.x
-
Wang L, van Belle G, Crane PK, et al. Subjective memory deterioration and future dementia in people aged 65 and older. J Am Geriatr Soc 2004;52:2045-2051 (Pubitemid 41725021)
-
(2004)
Journal of the American Geriatrics Society
, vol.52
, Issue.12
, pp. 2045-2051
-
-
Wang, L.1
Van Belle, G.2
Crane, P.K.3
Kukull, W.A.4
Bowen, J.D.5
McCormick, W.C.6
Larson, E.B.7
|